Abstract:Background: Sudden cardiac death (SCD) is a global public health issue, accounting for 10-20% of deaths in industrialized countries. Identification of modifiable risk factors may reduce SCD incidence. Methods: This umbrella review systematically evaluates published meta-analyses of observational and randomized controlled trials (RCT) for the association of modifiable risk and protective factors of SCD. Results: Fifty-five meta-analyses were included in the final analysis, of which 31 analyzed observational studies and 24 analyzed RCTs. Five associations of meta-analyses of observational studies presented convincing evidence, including three risk factors [diabetes mellitus (DM), smoking, and early repolarization pattern (ERP)] and two protective factors [implanted cardiac defibrillator (ICD) and physical activity]. Meta-analyses of RCTs identified five protective factors with a high level of evidence: ICDs, mineralocorticoid receptor antagonist (MRA), beta-blockers, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors in patients with HF. On the contrary, other established, significant protective agents [i.e., amiodarone and statins along with angiotensin-converting enzyme (ACE) inhibitors in heart failure (HF)], did not show credibility. Likewise, risk factors as left ventricular ejection fraction in HF, and left ventricular hypertrophy, non-sustain ventricular tachycardia, history of syncope or aborted SCD in pediatric patients with hypertrophic cardiomyopathy, presented weak or no evidence. Conclusions: Lifestyle risk factors (physical activity, smoking), comorbidities like DM, and electrocardiographic features like ERP constitute modifiable risk factors of SCD. Alternatively, the use of MRA, beta-blockers, SGLT-2 inhibitors, and ICD in patients with HF are credible protective factors. Further investigation targeted in specific populations will be important for reducing the burden of SCD. Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020216363, PROSPERO CRD42020216363.

Opportunities for sudden death prevention: Directions for new clinical and basic research

Sudden Cardiac Death: Epidemiology, Transient Risk, and Intervention Assessment

Prediction and Prevention of Sudden Death in the Brugada Syndrome

Trans-Atlantic Differences in Approach to Sudden Death Prevention in Patients With Hypertrophic Cardiomyopathy

The Genetic Basis of Sudden Cardiac Death: From Diagnosis to Emerging Genetic Therapies

Incidence, risk assessment and prevention of sudden cardiac death in cardiomyopathies

Cardiomyopathy and Sudden Cardiac Death: Bridging Clinical Practice with Cutting-Edge Research

Sudden Cardiac Death Prevention in Patients with Ischemic Heart Disease-Beyond the Ejection Fraction

Arrhythmias and Sudden Cardiac Death

The Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy

Risk and Protective Factors for Sudden Cardiac Death: An Umbrella Review of Meta-Analyses

The Lancet Commission to reduce the global burden of sudden cardiac death: a call for multidisciplinary action

Arrhythmic Sudden Cardiac Death in Heart Failure With Preserved Ejection Fraction: Mechanisms, Genetics, and Future Directions

Precision Medicine and Cardiac Channelopathies: Human iPSCs Take the Lead

Ventricular Arrhythmias in Ischemic Cardiomyopathy—New Avenues for Mechanism-Guided Treatment

Systematic Review of the Incidence of Sudden Cardiac Death in the United States

An Electrophysiologist Perspective on Risk Stratification in Heart Failure: Can Better Understanding of the Condition of the Cardiac Sympathetic Nervous System Help?

Prediction of sudden cardiac death using artificial intelligence: Current status and future directions

Sudden Cardiac Death in the General Population: Can We Improve Risk Stratification and Prevention?

Incidence and predictors of sudden cardiac death in patients with diastolic heart failure

Surviving sudden cardiac arrest—successes, challenges, and opportunities